



# The Anticancer Drug Bleomycin Shows Potent Antifungal Activity by Altering Phospholipid Biosynthesis

Mona Pokharel,<sup>a</sup> Paulina Konarzewska,<sup>a</sup> Jacques Y. Roberge,<sup>b</sup> Gil-Soo Han,<sup>c</sup> Yina Wang,<sup>a</sup> George M. Carman,<sup>c</sup>  Chaoyang Xue<sup>a,c,d</sup>

<sup>a</sup>Public Health Research Institute, New Jersey Medical School, Rutgers University, Newark, New Jersey, USA

<sup>b</sup>Molecular Design and Synthesis Core, Rutgers University Biomolecular Innovations Cores, Office for Research, Rutgers University, Piscataway, New Jersey, USA

<sup>c</sup>Rutgers Center for Lipid Research, New Jersey Institute for Food, Nutrition and Health, Rutgers University, New Brunswick, New Jersey, USA

<sup>d</sup>Department of Microbiology, Biochemistry and Molecular Genetics, New Jersey Medical School, Rutgers University, Newark, New Jersey, USA

**ABSTRACT** Invasive fungal infections are difficult to treat with limited drug options, mainly because fungi are eukaryotes and share many cellular mechanisms with the human host. Most current antifungal drugs are either fungistatic or highly toxic. Therefore, there is a critical need to identify important fungal specific drug targets for novel antifungal development. Numerous studies have shown the fungal phosphatidylserine (PS) biosynthetic pathway to be a potential target. It is synthesized from CDP-diacylglycerol and serine, and the fungal PS synthesis route is different from that in mammalian cells, in which preexisting phospholipids are utilized to produce PS in a base-exchange reaction. In this study, we utilized a *Saccharomyces cerevisiae* heterologous expression system to screen for inhibitors of *Cryptococcus* PS synthase Cho1, a fungi-specific enzyme essential for cell viability. We identified an anticancer compound, bleomycin, as a positive candidate that showed a phospholipid-dependent antifungal effect. Its inhibition on fungal growth can be restored by ethanolamine supplementation. Further exploration of the mechanism of action showed that bleomycin treatment damaged the mitochondrial membrane in yeast cells, leading to increased generation of reactive oxygen species (ROS), whereas supplementation with ethanolamine helped to rescue bleomycin-induced damage. Our results indicate that bleomycin does not specifically inhibit the PS synthase enzyme; however, it may affect phospholipid biosynthesis through disruption of mitochondrial function, namely, the synthesis of phosphatidylethanolamine (PE) and phosphatidylcholine (PC), which helps cells maintain membrane composition and functionality.

**IMPORTANCE** Invasive fungal pathogens cause significant morbidity and mortality, with over 1.5 million deaths annually. Because fungi are eukaryotes that share much of their cellular machinery with the host, our armamentarium of antifungal drugs is highly limited, with only three classes of antifungal drugs available. Drug toxicity and emerging resistance have limited their use. Hence, targeting fungi-specific enzymes that are important for fungal survival, growth, or virulence poses a strategy for novel antifungal development. In this study, we developed a heterologous expression system to screen for chemical compounds with activity against *Cryptococcus* phosphatidylserine synthase, Cho1, a fungi-specific enzyme that is essential for viability in *C. neoformans*. We confirmed the feasibility of this screen method and identified a previously unexplored role of the anticancer compound bleomycin in disrupting mitochondrial function and inhibiting phospholipid synthesis.

**KEYWORDS** *Cryptococcus neoformans*, phosphatidylserine synthase, PS synthase assay, inhibitor, bleomycin, mitochondria, ROS, antifungal drug

Opportunistic fungal infections remain a major cause of morbidity and mortality in immunocompromised patients. An estimated 1.5 to 2 million deaths worldwide every year are reported because of fungal infections, exceeding those killed by either malaria or

**Editor** Alexandre Alanio, Institut Pasteur

**Copyright** © 2022 Pokharel et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Chaoyang Xue, xuech@njms.rutgers.edu.

The authors declare no conflict of interest.

**Received** 8 March 2022

**Accepted** 10 August 2022

**Published** 29 August 2022


tuberculosis (1). Among fungal pathogens, *Cryptococcus neoformans*, a common cause of fungal meningitis in immunocompromised patients, results in approximately 223,100 cases and 181,100 deaths per year globally (2). The treatment of fungal infections, including cryptococcosis, is limited to only three antifungal classes. Therefore, there is an urgent need to identify novel drug targets for the development of new antifungal drugs. However, these efforts are difficult because fungi and their mammalian hosts are both eukaryotes and many proteins that make potential targets for antifungal development are also conserved in humans.

Of the three classes of drugs (polyenes, azoles, and echinocandins) currently available to treat invasive fungal infections, most of them have therapeutic limitations. Amphotericin B, the best known fungicidal drug of class polyene that inhibits fungal ergosterol is associated with an array of systemic toxicities (3, 4). The combination of amphotericin B and flucytosine, which is the current standard treatment for cryptococcal meningitis (5), is not ideal due to the emergence of flucytosine resistance in *C. neoformans* and hepatotoxicity (6). Azoles, the most widely used class, are fungistatic, and their role in antifungal therapy is threatened by the emergence of azole resistance (7). Triazole resistance in *Aspergillus fumigatus* has been reported to significantly complicate the treatment of patients with aspergillosis, primarily affecting patients with a compromised immune system (8). Echinocandins, which target beta-1,3-glucan synthase, are fungicidal, but ineffective against *C. neoformans*. Additionally, there is a growing concern of echinocandin resistance in *Candida* spp (9). Recently, resistance to all classes of antifungal drugs has been characterized in human-pathogenic fungal species (10). These drawbacks of low efficacy, toxicity, and resistance which are associated with current available antifungals clearly necessitate the development of more effective and safer antifungal drugs.

In fungi, phospholipids such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol (PG), phosphatidylinositol (PI), and phosphatidylserine (PS) are major constituents of the fungal cell membrane, playing a variety of roles in cell specificity and pathogenicity (11). Several studies have reported the relevance of fungal phospholipid biosynthetic enzymes in the development of antifungal drugs. Due to substantial differences in the metabolic pathways in fungi and their mammalian hosts, one such enzyme, PS synthase (Cho1), has been proposed as a potential drug target (12–15). In fungi, PS is synthesized in the endoplasmic reticulum (ER) by PS synthase (Cho1) from two substrates, CDP diacylglycerol (CDP-DAG) and serine (13, 16). In mammals, PS is produced through a base exchange reaction in which the choline in PC and the ethanolamine in PE are replaced with serine by the activity of PS synthases Pss1 and Pss2, respectively (16) (Fig. 1). The conservation of Cho1 in fungi implicates a broad-spectrum antifungal application, and the absence of its homolog in mammals implicates a potential low-toxicity effect, if any, to human hosts, further indicating PS synthase inhibitor as a potential compound for antifungal development.

Disruption of PS synthase is known to impair varied functions in different fungi. In *Saccharomyces cerevisiae*, the *cho1*Δ mutant (*Sccho1*Δ) is viable but an ethanolamine/choline auxotroph (17). This mutant can only grow when supplemented with ethanolamine or choline, which is utilized to synthesize PE and PC via the Kennedy pathway (18). The homozygous *cho1*Δ/Δ mutant in *C. albicans* (*Cacho1*Δ/Δ) is viable and auxotrophic for ethanolamine (13), and its growth is very poorly rescued by choline supplementation. This mutant is avirulent in a murine model of systemic candidiasis, indicating the essentiality of *CaCho1* for virulence (13). The PS synthase mutant from fission yeast *S. pombe* (*pps1*Δ) is auxotrophic for ethanolamine and its growth defect cannot be rescued by choline (19). Unlike PS synthase in other fungi, Cho1 in *C. neoformans* (*CnCho1*) has been shown to be essential, and strains deficient in PS due to disruption of Cho1 cannot be rescued by ethanolamine or choline despite the presence of an active Kennedy pathway (20).

In this study, we established a yeast heterologous expression system by expressing *C. neoformans* *CHO1* in a *S. cerevisiae* *cho1*Δ mutant strain and utilized this system to screen compound collections for chemicals which specifically inhibit Cho1 function in *C. neoformans*. We screened a total of ~3,800 chemical compounds from three collections, namely, the Pathogen Box collection, the National Institutes of Health Clinical



**FIG 1** *CnCHO1* expression in *Sccho1Δ* mutant rescued its growth arrest phenotype. (A) Wild-type (WT) *S. cerevisiae* strain (*Sc WT*) grown in a 96-well plate at 30°C for 48 h showed no difference in growth on SD medium, both in presence and absence of ethanolamine. *Sccho1Δ* mutant failed to grow on SD medium lacking ethanolamine, while it grew on ethanolamine-supplemented medium. *Sccho1Δ* mutant expressing *CnCHO1* (*Sccho1Δ+CnCHO1*) grew well even in the absence of ethanolamine complementing the growth arrest. (B) Growth was evaluated via absorbance measurements at an optical density of 600 nm ( $OD_{600}$ ) using a plate reader. (C) PS synthesis in fungi and mammals. In yeast *de novo* pathway of phosphatidylserine (PS) synthesis, endoplasmic reticulum (ER)-localized PS synthase, and Cho1 converting CDP diacylglycerol (CDP-DAG) to PS. PS is subsequently converted to phosphatidylethanolamine (PE) by inner mitochondrial membrane-localized PS decarboxylase 1 (Psd1). PE can be exported to the ER for further conversion to phosphatidylcholine (PC). Ethanolamine (Etn) and choline (Cho) from cytosol can be utilized to form PE and PC, respectively, via the Kennedy pathway. In mammals, PS is produced through a base exchange reaction in which choline in PC and ethanolamine in PE are replaced with serine by the activity of PS synthases Pss1 and Pss2, respectively.

Collection (NCC), and the FDA-approved drug collection. Several compounds were identified based on their high potency and differential growth inhibition on synthetic defined (SD) medium in the presence and absence of ethanolamine. One of these is bleomycin, an anticancer agent commonly used in the treatment of multiple malignancies, including testicular cancer, head and neck cancer, cervical and uterine cancer, and pleural effusion caused by cancerous tumors (21). The mechanism of bleomycin-induced cytotoxicity is not entirely clear, but it likely includes oxidative damage that induces single- or double-stranded DNA breaks (22). This drug can disrupt mitochondrial function and induce the production of reactive oxygen species (ROS) (23). In our study, we explored the potential action of bleomycin in yeast cells and tested whether it can inhibit Cho1. Although our secondary screening yielded bleomycin as a promising hit, we found that this compound may not directly target Cho1. Because synthesized PS is translocated from the ER to the mitochondrial membrane to produce PE, our study demonstrated that bleomycin-induced mitochondrial dysfunction indirectly compromised phospholipid synthesis and homeostasis, e.g., PE and PC, leading to an inhibitory effect on fungal cells. In summary, our study identified the anticancer drug bleomycin as a potent antifungal target compound and revealed its potential mechanism in inhibiting fungal phospholipid synthesis.

## RESULTS

**Establishment of the yeast heterologous expression system for chemical screen of PS synthase.** Our previous study demonstrated that PS synthase Cho1 is an essential protein required for fungal viability and virulence in *C. neoformans* (20). In *S. cerevisiae*, the

*cho1Δ* mutant (*Sccho1Δ*) is viable but ethanolamine-auxotrophic (17). When grown in SD medium, the *Sccho1Δ* mutant grew in the presence of 1 mM ethanolamine but failed to grow in its absence (Fig. 1A and B). This mutant was able to take up exogenous ethanolamine to synthesize PC and PE via the Kennedy pathway (Fig. 1C).

*Sccho1Δ* expressing the *Cryptococcus CHO1* gene (*CnCHO1*) was able to rescue its growth defect in ethanolamine-supplemented SD liquid medium. Therefore, we developed a screening assay based on this *Sccho1Δ+CnCHO1* complemented strain for functional screening of *Cryptococcus* PS synthase inhibitors. We predicted that *CnCho1* inhibitor would block growth of the *Sccho1Δ+CnCHO1* strain on medium lacking ethanolamine, mimicking an ethanolamine-auxotrophic phenotype.

**Primary screen identified compounds with inhibitory activity against *C. neoformans*.** Using the *S. cerevisiae* heterologous expression system (*Sccho1Δ+CnCHO1*), we screened ~3,800 compounds from different collections for those which inhibit yeast growth in synthetically defined uracil dropout medium (SD-Ura). The primary objective of our screen was to identify not only potent antifungal compounds but also potential specific Cho1 enzyme inhibitors. We tested all 3 compound collections at a starting concentration of 5  $\mu\text{M}$  and identified 46 compounds with MICs of 5  $\mu\text{M}$  or lower from the FDA-approved drug collection. The Pathogen Box collection contained 6 compounds with MICs of 5  $\mu\text{M}$  or lower, and NCC screening identified 7 compounds with MICs of 5  $\mu\text{M}$  or lower. The preliminary screening yielded a diverse variety of compounds with various therapeutic uses like antihypertensive, antipsychotic, antihistamine, in addition to different known antifungal agents. The commercial use of each drug is listed together with their MIC values in Table 1. Some highly potent compounds such as thimerosal, temsirolimus, rapamycin, and phenylmercuric acetate were tested at lower concentrations. They exhibited effective antifungal activities against both *S. cerevisiae* and *C. neoformans* (MICs listed in Tables 1 and 2).

**Secondary screening of compounds that confer rescue in ethanolamine supplemented media.** The secondary screening was based on rescue phenotypes in ethanolamine-containing medium, which indicated that the identified drug compounds targeted PS synthesis. We tested the effects of different concentrations of chemical compounds on their ability to rescue growth defect in SD medium supplemented with 1 mM ethanolamine (SD+Etn). Growth was evaluated via absorbance measurements at an optical density of 600 nm ( $\text{OD}_{600}$ ) using a plate reader, and the results were presented as a heat map (Fig. 2). For most of the possible drug targets, cell growth was not restored when growth medium was supplemented with 1 mM ethanolamine. Only bleomycin (plate 14 H09) and bleomycin sulfate (plate 21 C05) from the FDA-approved drug collection showed rescue phenotypes, as indicated by more than 5-fold increases in MICs in medium supplemented with ethanolamine compared to those in the medium lacking ethanolamine (Fig. 2A).

We tested bleomycin (purchased from TCI America, Portland, OR) activity against *S. cerevisiae* wild type (WT, YUX104), *Sccho1Δ* (YUX105), and *Sccho1Δ+CnCHO1* (YUX106) strains and *C. neoformans* wild-type strain (H99) in SD and SD+Etn media (Fig. 3A). The MICs of bleomycin against the *Sccho1Δ+CnCHO1* strain were 1.25  $\mu\text{M}$  in SD medium and 10  $\mu\text{M}$  in SD+Etn medium, while those H99 were 5  $\mu\text{M}$  and 10  $\mu\text{M}$ , indicating an 8-fold increase in MIC against *Sccho1Δ+CnCHO1* and a 2-fold increase in H99 in the ethanolamine-supplemented medium (SD+Etn), respectively (Fig. 3B). As expected, the *Sccho1Δ* mutant did not grow in the absence of ethanolamine and grew poorly in an ethanolamine-supplemented medium without bleomycin. The *Sc* WT strain showed 4-fold increases in MIC values (2.5  $\mu\text{M}$  in SD and 10  $\mu\text{M}$  in SD+Etn) (Fig. 3B). Thus, our data demonstrated that ethanolamine addition can rescue the antifungal activity of bleomycin in both *S. cerevisiae* and *C. neoformans*, suggesting that bleomycin may inhibit PS synthesis.

**Bleomycin does not inhibit PS synthase enzyme activity.** To determine whether bleomycin directly inhibits Cho1 enzyme activity, a PS synthase assay was performed for *S. cerevisiae* WT (YUX104) and *Sccho1Δ+CnCHO1* (YUX106) strains. In our previous study, we showed that the *Sccho1Δ+CnCHO1* strain restored PS synthesis activity in comparison to a *Sccho1Δ* mutant which completely lacked PS synthase activity (20).

**TABLE 1** Chemical compounds with MICs of  $\leq 5 \mu\text{M}$  when tested against *Sccho1* $\Delta$ +*CnCHO1* strain<sup>a</sup>

| Compounds and collection sources | Compound ID  | MICs ( $\mu\text{M}$ ) |           | Commercial use   |
|----------------------------------|--------------|------------------------|-----------|--|
|                                  |              | On SD                  | On SD+Etn |  |
| FDA-approved                     |              |                        |           |  |
| Atorvastatin calcium             |              | 5                      | 5         | Cholesterol-lowering medication                        |
| Cetylpyridinium chloride         |              | 5                      | 5         | Antiseptic properties                                  |
| Hexachlorophene                  |              | 5                      | 5         | Disinfectant   |
| Oxyquinoline sulfate             |              | 5                      | 1.25      | Antiseptic and disinfectant                            |
| Chloroxine                       |              | 5                      | 10        | Antibacterial  |
| Sirolimus                        |              | 5                      | 5         | Immunosuppressant                                      |
| Broxaldine                       |              | 5                      | 5         | Antiprotozoal  |
| Cetrimonium bromide              |              | 2.5                    | 2.5       | Antiseptic   |
| Miltefosine                      |              | 5                      | 5         | Anti-leishmanial                                       |
| Carmofur                         |              | 5                      | 5         | Antineoplastic   |
| Broxyquinoline                   |              | 5                      | 5         | Antiprotozoal  |
| Crystal violet                   |              | 5                      | 2.5       | Antibacterial, antifungal, and anthelmintic properties |
| Posaconazole                     |              | 5                      | 10        | Antifungal drug  |
| Chloroxine                       |              | 5                      | 5         | Antibacterial  |
| Sulconazole                      |              | 5                      | 2.5       | Antifungal drug  |
| Itraconazole                     |              | 5                      | 5         | Antifungal drug  |
| Miltefosine                      |              | 5                      | 5         | Antimicrobial and anti-leishmanial                     |
| Clotrimazole                     |              | 2.5                    | 2.5       | Antifungal drug  |
| Gentian violet                   |              | 2.5                    | 2.5       | Antibacterial, antifungal, and anthelmintic properties |
| Amorolfine hydrochloride         |              | 2.5                    | 0.625     | Antifungal drug  |
| Nitroxoline                      |              | 2.5                    | 2.5       | Antibacterial  |
| Ebselen                          |              | 2.5                    | 2.5       | Antioxidant activity                                   |
| Disulfiram                       |              | 2.5                    | 1.25      | Alcoholism medication                                  |
| Econazole                        |              | 2.5                    | 1.25      | Antifungal drug  |
| Nitroxoline                      |              | 2.5                    | 1.25      | Antineoplastic   |
| Bleomycin                        |              | 1.25                   | 10        | Antineoplastic   |
| Econazole nitrate                |              | 1.25                   | 0.312     | Antifungal drug  |
| Disulfiram                       |              | 1.25                   | 2.5       | Alcoholism medication                                  |
| Econazole nitrate                |              | 1.25                   | 0.312     | Antifungal drug  |
| Caspofungin acetate              |              | 1.25                   | 1.25      | Antifungal drug  |
| Fluorouracil                     |              | 0.625                  | 0.625     | Antineoplastic   |
| Oxiconazole nitrate              |              | 0.312                  | 0.312     | Antifungal drug  |
| Tioconazole                      |              | 0.625                  | 0.625     | Antifungal drug  |
| Butoconazole                     |              | 0.625                  | 0.312     | Antifungal drug  |
| Sulconazole nitrate              |              | 0.625                  | 0.625     | Antifungal drug  |
| Cycloheximide                    |              | 0.625                  | 0.625     | Fungicide  |
| Thiram                           |              | 0.625                  | 0.625     | Fungicide  |
| Climbazole                       |              | 0.625                  | 0.625     | Antifungal drug  |
| Bleomycin sulfate                |              | 0.625                  | 10        | Antineoplastic   |
| Miconazole nitrate               |              | 0.312                  | 0.312     | Antifungal drug  |
| Voriconazole                     |              | 0.312                  | 0.312     | Antifungal   |
| Pyrrithione zinc                 |              | 0.156                  | 0.156     | Fungistatic and bacteriostatic                         |
| Thimerosal                       |              | 0.038                  | 0.038     | Antiseptic and antifungal agent                        |
| Temsirolimus                     |              | 0.038                  | 0.156     | Antineoplastic   |
| Rapamycin (sirolimus)            |              | 0.019                  | 0.3125    | Antineoplastic   |
| Phenylmercuric acetate           |              | 0.0095                 | 0.0095    | Preservative and disinfectant properties               |
| Pathogen Box                     |              |                        |           |  |
| NA                               | MMV688271    | 5                      | 5         |  |
| NA                               | MMV102872    | 5                      | 5         |  |
| Iodoquinol                       | MMV002817    | 2.5                    | 2.5       | Amebicidal   |
| Posaconazole                     | MMV688774    | 0.625                  | 0.625     | Antifungal drug  |
| NA                               | MMV687807    | 0.625                  | 0.312     |  |
| Difenoconazole                   | MMV688943    | 0.625                  | 0.625     | Fungicide  |
| NCC                              |              |                        |           |  |
| Hexachlorophene                  | SAM002554903 | 5                      | 5         | Antibacterial  |

(Continued on next page)



TABLE 1 (Continued)

| Compounds and collection sources | Compound ID  | MICs ( $\mu\text{M}$ ) |           | Commercial use  |
|----------------------------------|--------------|------------------------|-----------|-----------------|
|                                  |              | On SD                  | On SD+Etn |                 |
| Econazole nitrate                | SAM002554898 | 2.5                    | 5         | Antifungal drug |
| Chloroxine                       | SAM002554895 | 1.25                   | 1.25      | Antibacterial   |
| Miconazole nitrate               | SAM002264623 | 1.25                   | 1.25      | Antifungal drug |
| Voriconazole                     | SAM001246664 | 0.625                  | 0.625     | Antifungal drug |
| Itraconazole                     | SAM001246679 | 0.625                  | 0.625     | Antifungal drug |
| Oxiconazole nitrate              | SAM001246724 | 0.312                  | 0.312     | Antifungal drug |

<sup>a</sup>SD, synthetic defined medium; SD+Etn, SD medium supplemented with 1 mM ethanolamine; NCC, NIH Clinical Collection.


Based on that observation, we predicted reduced PS levels in the *Sccho1Δ+CnCHO1* strain under the bleomycin-treated condition if bleomycin specifically inhibits PS synthase enzyme, Cho1. Interestingly, we did not detect a significant difference in Cho1 enzyme activity for cells treated with 5 mM bleomycin compared to the untreated control in our direct PS synthase assay (Fig. 3D). These data show that bleomycin does not specifically inhibit the PS synthase enzyme.

**Bleomycin damages function of mitochondrial membrane.** Mitochondria are an important source of reactive oxygen species (ROS) (24, 25) which can lead to oxidative damage to mitochondrial proteins, membranes, and DNA, impairing its wide range of metabolic functions. Because PS synthesized in the ER needs to be translocated to the mitochondrial membrane to synthesize PC, we hypothesize that bleomycin inhibits fungal phospholipid production by targeting mitochondria function rather than by directly inhibiting Cho1 enzyme activity. To explore whether bleomycin targets mitochondrial function in *C. neoformans*, we used mitochondria-specific fluorescent dye MitoTracker Deep Red FM (Thermo Fisher Scientific, Waltham, MA) because its accumulation depends on mitochondrial membrane potential activity (21). After 10 h of treatment with bleomycin at a dose of  $2 \times \text{MIC}$  (2.5  $\mu\text{M}$  for *S. cerevisiae* and 5  $\mu\text{M}$  for *C. neoformans*), mitochondrial function was monitored based on the retention of MitoTracker dye. Fluorescence imaging of MitoTracker probe exhibited a significant reduction of fluorescence intensity in ethanolamine-lacking, bleomycin-treated cells of both *Saccharomyces* and *Cryptococcus* spp. (Fig. 4A and B), indicating disrupted mitochondrial function. In contrast, bleomycin-treated cells grown in SD+Etn medium retained the dye, suggesting that the mitochondrial membrane was still intact and functional. All nuclei were visualized by Hoechst 33342 staining to determine intact cells and overall cell morphology. At the concentration used in our assay, there was no obvious difference in nuclear staining upon 10 h treatment with bleomycin. Furthermore, flow cytometry analysis revealed a reduced fluorescence signal intensity of MitoTracker dye in bleomycin-treated cells in the absence of ethanolamine, confirming the microscopic observations (Fig. 4C and E) for *Saccharomyces* and *Cryptococcus* yeast cells, respectively. Untreated yeast cells did not show a significant difference in the intensity of the MitoTracker signal when grown in SD medium with or without ethanolamine supplementation. An overlaid histogram of MitoTracker fluorescence intensity (blue, SD; red, SD+Etn) clearly demonstrates a loss of membrane potential in bleomycin-treated yeast cells in SD medium alone compared to that in ethanolamine-supplemented medium for both *S. cerevisiae* and *C. neoformans* (Fig. 4D and F). This indicates that bleomycin treatment led to perturbation of the mitochondrial membrane

TABLE 2 Highly potent compounds when tested against *Cryptococcus* WT strain H99<sup>a</sup>

| Compounds              | MIC ( $\mu\text{M}$ ) |
|------------------------|-----------------------|
| Temsirolimus           | 2.5                   |
| Rapamycin (sirolimus)  | 0.625                 |
| Pyrrithione zinc       | 0.156                 |
| Thimerosal             | 0.078                 |
| Temsirolimus           | 0.038                 |
| Phenylmercuric acetate | 0.0195                |


<sup>a</sup>WT, wild-type.



**FIG 2** Secondary screening of compound collections identified compounds with some specificity against PS synthase. Primary screening at 5  $\mu\text{M}$  starting concentration identified 46 chemical compounds in the FDA-approved drug collection (A), 6 compounds in the Pathogen Box collection (B), and 7 compounds in the NIH Clinical Collection (NCC) set (C). All chemical compounds from the primary screen were further examined for rescue of growth arrest in the presence of 1 mM ethanolamine (SD+Etn) compared to that in SD medium lacking ethanolamine (SD). Growth of *Sccho1 $\Delta$ +CnCHO1* strain (1,000 cells) in 96-well plates in SD (left panel) and SD+Etn medium (right panel) at final concentrations of chemical compounds of 5, 2.5, 1.25, 0.625, 0.312, and 0  $\mu\text{M}$  DMSO (dimethyl sulfoxide) was evaluated via absorbance measurements at  $\text{OD}_{600}$  using a plate reader after 48 h of incubation at 30°C. Results are represented as a heat map, with green indicating growth and purple indicating no growth. While most compounds showed similar ranges of growth inhibition, bleomycin and bleomycin sulfate (indicated by black arrowheads at the sides of the heat maps) showed some degree of growth rescue.

potential in SD medium, and that the membrane was protected to some extent in the medium supplemented with ethanolamine.


**Bleomycin induces ROS accumulation.** An impaired mitochondrial function increases the production of reactive oxygen species in yeast cells (26). Furthermore,



**FIG 3** Determination of MICs and PS synthase activity. (A) MIC assay was performed on 96-well plate for indicated strains to determine the rescue effect of bleomycin (blm) in the presence of ethanolamine. (B) The lowest concentration that inhibited visible growth after 48 h of incubation is interpreted as the MIC. (C) Structure of bleomycin sulfate. (D) PS synthase activity in *S. cerevisiae* strains. Compared to the untreated condition, *Sc* WT and *Sccho1Δ+CnCHO1* with addition of 5 mM bleomycin showed no difference in PS synthase activity, indicating that bleomycin is not a specific inhibitor of Cho1. Data are represented as means  $\pm$  standard deviation and statistical analysis was performed by unpaired two-tailed Student's *t* test.

independent of mitochondrial membrane potential damage, bleomycin itself is also known to cause an increase in ROS, resulting in oxidative stress and apoptosis (27). Therefore, we measured ROS levels in yeast cells to determine whether bleomycin treatment contributes to increased ROS accumulation and whether it varied when grown in ethanolamine-supplemented SD medium. Yeast cells grown overnight in SD medium were transferred to SD and SD+Etn medium for an additional 4 h followed by 10 h treatment with bleomycin. Intracellular ROS accumulation was measured using fluorescent dyes, 2',7'-dichlorodihydrofluorescein diacetate (H<sub>2</sub>DCFDA) and dihydroethidium (DHE). The readout of both probes is a fluorescence signal that enables the measurement of ROS production in fungal cells. The H<sub>2</sub>DCFDA assay is based on intracellular esterase action on non-fluorescent H<sub>2</sub>DCFDA to release an intermediate product which reacts with ROS to form the fluorescent product 2',7'-dichlorofluorescein (DCF) (28). Fluorescence imaging of H<sub>2</sub>DCFDA probe demonstrated a significant increase in ROS production in cells grown in SD with bleomycin compared to that in SD+Etn for both *S. cerevisiae* and *C. neoformans* yeast cells (Fig. 5A and B), respectively. Concurrent with microscopic data, flow cytometry analysis revealed increased fluorescence intensity of the H<sub>2</sub>DCFDA probe in ethanolamine-lacking, bleomycin-treated cells






**FIG 4** Analysis of mitochondrial function in bleomycin-treated yeast cells. The *Sccho1*+*CnCHO1* strain and *C. neoformans* WT (H99) cultured in SD and SD+Etn medium were treated for 10 h with 2.5  $\mu$ M and 5  $\mu$ M bleomycin, respectively. Cells stained with MitoTracker Deep Red FM and Hoechst 33342 were viewed under a fluorescence microscope. Under the bleomycin-treated condition, both *Sccho1*+*CnCHO1* (A) and H99 (B) showed accumulation of fluorescence dye in ethanolamine supplemented-medium, indicating normal mitochondrial membrane function. Scale bar = 10  $\mu$ m. Flow cytometric analysis of MitoTracker-stained cells revealed higher mitochondrial membrane potential in yeast cells grown in ethanolamine-lacking medium. (C and E) Representative graphs of MitoTracker with flow cytometry for bleomycin-treated *Sccho1* $\Delta$ +*CnCHO1* (C) and H99 cells (E), respectively. (D and F) Overlaid fluorescence histogram of MitoTracker for cell populations from bleomycin-treated *Sccho1* $\Delta$ +*CnCHO1* (D) and H99 (F) cells. Values represent the average of three independent experiments, and error bars indicate standard deviation. Student's *t* test was performed to determine statistical significance. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; ns, not significant.

of both *Saccharomyces* and *Cryptococcus* spp. (Fig. 5C and D). Untreated yeast cells showed no significant difference in the intensity of ROS probe staining when grown in medium with or without ethanolamine. A histogram of ROS fluorescence intensity (green, SD; red SD+Etn) clearly exhibited increased ROS accumulation in bleomycin-treated yeast cells in SD medium alone compared to that in ethanolamine-supplemented medium in both yeast species (Fig. 5D and F). This observation suggests that ethanolamine in the medium protected the yeast cells from bleomycin-induced damage.

To confirm the findings from H<sub>2</sub>DCFDA probe data, we employed another fluorescent probe, DHE, to measure ROS production. Fluorescence signal resulting from the oxidation of DHE to 2-hydroxyethidium by superoxide has been used as an assay to measure ROS. The same procedure for yeast cell preparation was followed for the DHE assay, except that we utilized a microplate reader to detect fluorescence signal. Similar to the previous results from the H<sub>2</sub>DCFDA assay, bleomycin-treated yeast cells in SD medium showed increased ROS accumulation compared to those grown in ethanolamine-supplemented medium for both *Saccharomyces* and *Cryptococcus* spp. (Fig. 5G and F). The increased ROS accumulation by both methods upon treatment with bleomycin in SD medium lacking ethanolamine demonstrates increased the susceptibility of yeast cells to bleomycin-induced damage.

## DISCUSSION

There is an urgent public health need for novel, potent antifungal drugs due to the increase in life-threatening fungal infections. This study was designed to screen for



**FIG 5** Effect of bleomycin treatment on reactive oxygen species (ROS) production in yeast cells. Overnight-incubated yeast cells were transferred to SD and SD+Etn media for 4 h before bleomycin treatment for 10 h. Intracellular ROS accumulation was assayed using 2',7'-dichlorodihydrofluorescein diacetate (H<sub>2</sub>DCFDA) staining and visualized under a fluorescence microscope. Scale bar = 10 μm. Supplementation of ethanolamine decreased ROS accumulation in both strains, *Sccho1Δ+CnCHO1* (A) and H99 (B). (C and E) Representative graph of dichlorofluorescein (DCF) with flow cytometry for bleomycin-treated *Sccho1Δ+CnCHO1* (C) and H99 (E) cells, respectively. (D and F) Overlaid fluorescence histogram of DCF for cell populations from bleomycin-treated *Sccho1Δ+CnCHO1* (D) and H99 (F) cells. (G and H) Intracellular ROS measurement using dihydroethidium (DHE). DHE fluorescence in *Sccho1Δ+CnCHO1* (G) and H99 (H) cells was analyzed using a microplate reader. Values represent the average of three independent experiments, error bars indicate standard deviation. Student's *t* test was performed to determine statistical significance. \*, *P* < 0.05; ns, not significant.

compounds with antifungal activity against PS synthase, which represents a new fungal target because it is fungi-specific and essential for *Cryptococcus* viability. To date, no direct inhibitor of fungal PS synthase enzymes has been identified to have antifungal drug potential. Previous screens for inhibitors of PS synthase (Cho1) in *Candida* spp. identified the small molecule SB-224289, a serotonin receptor antagonist, as a positive hit; however, a PS synthase assay displayed no change in the activity of Cho1 (29). In our study, we developed a whole-cell functional screen strategy using a yeast heterologous expression system to screen for inhibitors of *Cryptococcus* PS synthase. Of all those which displayed antifungal properties, bleomycin, an anticancer agent, was identified as a promising candidate due to its low MICs against both *S. cerevisiae* and *C. neoformans* and its ability to restore growth inhibition by the addition of ethanolamine. Our study, hence, focuses on the mechanism of bleomycin inhibition of *C. neoformans*.

Bleomycin has been clinically used as a cancer chemotherapeutic agent for the treatment of several types of malignancies; however, its mechanism of action remains unclear and is limited mostly to cancer cells. The cytotoxic action of bleomycin has been attributed to an activated form that induces sequence-specific single- and

double-stranded DNA breaks (30), RNA degradation (31, 32), and lipid peroxidation (33). The potential antifungal activity of bleomycin has been explored in some fungi. It has been reported to have MICs of 6.4  $\mu\text{g}/\text{mL}$  in *C. neoformans*, 0.39 to 12.5  $\mu\text{g}/\text{mL}$  in *Candida* spp., and 3.2  $\mu\text{g}/\text{mL}$  in *S. cerevisiae* (34). In another study, bleomycin showed an MIC of 3.2  $\mu\text{g}/\text{mL}$  against *Aspergillus fumigatus*, with inhibition of conidial germination and hyphal development and a defect in cell wall septation (35). The direct target of bleomycin on fungal cells such as *C. neoformans* remains unknown.

To determine whether bleomycin directly inhibits PS synthase Cho1 function, we performed a PS synthase enzyme activity assay. Interestingly, no significant difference in Cho1 enzyme activity was detected in the presence of bleomycin treatment, suggesting that bleomycin may not specifically inhibit Cho1 function to block PS synthesis. This result explains our MIC assay data, in which not only the *Sccho1* $\Delta$ +*CnCHO1* strain but also *Sc* WT and *Cn* WT showed exogenous ethanolamine-dependent MIC changes. While *Sccho1* $\Delta$ +*CnCHO1* was demonstrated to be an ethanolamine auxotroph, *Sc* WT and *Cn* WT also showed some degree of growth rescue in the presence of ethanolamine (Fig. 3A).

Because reports have shown that some anticancer drugs target mitochondrial function to induce apoptosis (36), and PS synthesized in the ER is translocated to the mitochondrial membrane to produce PE through PS decarboxylase, we assessed bleomycin's potential to inhibit mitochondrial function. In our study, we observed reduced mitochondrial membrane potential in bleomycin-treated yeast cells grown in SD medium, but not in cells grown in ethanolamine-supplemented medium (Fig. 4). As with the mitochondrial-staining results, the ROS assay also indicated greater ROS accumulation in bleomycin-treated yeast cells grown in SD medium than in cells grown in SD medium supplemented with ethanolamine (Fig. 5). Increased ROS production in yeast cells grown in SD medium could be an independent effect of bleomycin or the result of mitochondrial disruption. Taken together, both the mitochondrial staining and ROS assays indicate bleomycin-induced damage in yeast cells grown in SD medium and that cells are somewhat protected in SD+Etn medium. We hypothesize that bleomycin-induced inhibition in yeast cells could be the result of impaired mitochondrial function which possibly disrupts enzymes located in the mitochondrial membrane, including PS decarboxylase Psd1, which synthesizes PE from PS. Studies have shown that cardiolipin (CL) and PE are essential phospholipids for mitochondrial respiratory function (37), and that their absence or reduced levels are known to cause serious growth defects in cells (38). Our observation showed that exogenous supplementation of ethanolamine helped yeast cells preserve membrane functionality without drastically affecting the cells upon bleomycin treatment. In contrast, in the absence of ethanolamine, mitochondrial impairment induced by bleomycin treatment drastically decreased levels of phospholipids (e.g., PE) inside the cells, making them more susceptible to damage. It is clear that in *S. cerevisiae*, the Kennedy pathway plays a critical role in PE and PC synthesis when enzymes of the *de novo* pathway are disrupted (39). Enabling PE and PC synthesis via the Kennedy pathway, the *Sccho1* $\Delta$  mutant can grow if ethanolamine or choline are exogenously supplied (40). We believe that bleomycin treatment damaged the mitochondria, where phospholipid biosynthesis enzymes localize, consequently disrupting one or many key pathway enzymes. The supplementation of ethanolamine, however, activated the ER-localized Kennedy pathway, which bypasses the mitochondria to generate PE and PC to support biogenesis and maintain cell viability. This hypothesis will be tested in future studies.

In addition to identifying bleomycin and its phospholipid-dependent antifungal effect, our screen also led to the identification of an extensive list of known antifungal and non-antifungal compounds against *S. cerevisiae* and *C. neoformans* (Table 1). Our screen of the Pathogen Box collection identified several antifungal drugs which were also identified in a previous study of *C. neoformans* and *C. albicans*, e.g., difenoconazole, posaconazole, MMV688271 (41), and MMV687807 in *C. albicans* (42). Sirolimus or rapamycin, initially discovered as an antifungal agent (43) and then as an immunosuppressive drug, was shown to have robust antifungal activity against both *S. cerevisiae*

**TABLE 3** Strains used in this study<sup>a</sup>

| Strains | Genotype  | References |
|---------|---|------------|
| YUX104  | <i>MATa ade2-1 can1-100 his3-11,15 leu2-3,112 trp1-1 ura3-1</i> [pTH19] ( <i>Saccharomyces cerevisiae</i> WT)                         | 20         |
| YUX105  | <i>MATa ade2-1 can1-100 his3-11,15 leu2-3,112 trp1-1 ura3-1 cho1Δ::TRP1</i> [pTH19] ( <i>Sccho1</i> )                                 | 20         |
| YUX106  | <i>MATa ade2-1 can1-100 his3-11,15 leu2-3,112 trp1-1 ura3-1 cho1Δ::TRP1</i> [pTH19-Cn <i>CHO1</i> ] ( <i>Sccho1</i> +Cn <i>CHO1</i> ) | 20         |
| H99     | <i>MATα Cryptococcus neoformans</i> WT  | 52         |

<sup>a</sup>WT, wild-type.

(MIC = 0.019  $\mu$ M) and *C. neoformans* (MIC = 0.625  $\mu$ M). Similar studies in both *C. albicans* and *S. cerevisiae* showed inhibition by low concentrations of rapamycin (MIC = <0.0625  $\mu$ g/mL) (44). Some potent antifungal compounds such as pyrithione zinc (MIC = 0.156  $\mu$ M), thimerosal (MIC = 0.078  $\mu$ M), temsirolimus (MIC = 0.038  $\mu$ M), and phenylmercuric acetate (MIC = 0.0195  $\mu$ M) were also identified. However, we did not further investigate them because they are being used as antifungals. The antifungal properties of zinc pyrithione (45), widely used in anti-dandruff treatment, and mercury-based compounds such as thimerosal (46) and phenylmercuric acetate (47), which are effective against ocular-pathogenic fungi, are used in ophthalmic medication.

In summary, we found that bleomycin exhibits potent antifungal activity and that the concentration of available ethanolamine in the medium changes the effect of bleomycin treatment in yeast cells. Our data indicate that bleomycin inhibition of fungal growth may not be due to directly targeting PS synthase Cho1, but rather the phospholipid synthesis pathway downstream of PS production. The mechanism of Cho1 involvement in this process remains to be explored. Further studies are warranted to better understand bleomycin's mode of action in the phospholipid *de novo* biosynthetic pathway and the interplay between the biosynthetic and Kennedy pathways in fungal cells.

## MATERIALS AND METHODS

**Yeast strains and media.** All strains used in this study are listed in Table 3. Fungal strains were grown in synthetic dropout medium lacking uracil (SD-Ura) (0.67%, yeast nitrogen base without amino acids, 2% glucose with appropriate supplement of 1 $\times$  all amino acids except uracil), except for strain YUX105 which was maintained in SD-Ura supplemented with ethanolamine. All compound screening assays were performed on SD-Ura medium with or without 1 mM ethanolamine (SD+Etn and SD, respectively). Overnight cultures were grown in liquid SD-Ura medium in a shaking incubator at 30°C and 200 rpm.

**Drug library and drug reconstitution.** The Pathogen Box collection ( $n = 400$ ) was kindly provided by the Medicines for Malaria Venture (MMV) (<https://www.mmv.org>) with a stock concentration of 10 mM/10  $\mu$ L compound in each well in dimethyl sulfoxide (DMSO). The National Institutes of Health Clinical Compound Collection (NCC) ( $n = 707$ ) was provided by the NIH Small Molecule Repository (<https://pubchem.ncbi.nlm.nih.gov/source/NIH%20Clinical%20Collection>) with a stock concentration of 10 mM/10  $\mu$ L compound in each well. Compounds from both collections were dissolved in filter-sterilized DMSO (Sigma-Aldrich, St. Louis, MO) and diluted in sterile double-distilled water (ddH<sub>2</sub>O) to make stock solutions of 10  $\mu$ M/ $\mu$ L. The FDA-approved drug collection ( $n = 2662$ ) was provided by Molecular Design and Synthesis Core, Rutgers University with concentrations of 5,000 pmol compound in each well. The dried-out compounds were completely dissolved in 10  $\mu$ L DMSO and diluted in sterile ddH<sub>2</sub>O to make working solutions of 50  $\mu$ M compound. All stock chemical compounds in a master plate were stored at  $-80^{\circ}\text{C}$ . A large quantity of bleomycin sulfate (mixture) was purchased from TCI America (Thermo Fisher Scientific) and prepared at 10 mM using DMSO as the solvent.

**Primary screening of drug library.** Screening of the compounds was conducted in a sterile polystyrene, flat-bottomed 96-well plate (Corning). Overnight cultures in SD-Ura medium were washed twice in sterile phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na<sub>2</sub>HPO<sub>4</sub>, 1.8 mM KH<sub>2</sub>PO<sub>4</sub>) resuspended in fresh SD medium, and incubated for at least 2 h to make fresh yeast suspension. A total of 1,000 yeast cells, as measured by hemocytometer, were exposed to identical starting concentrations of 5  $\mu$ M drug for each library, to a final volume of 100  $\mu$ L SD medium, and incubated without agitation at 30°C. Chemical compounds which visibly inhibited yeast cell growth after 48 h were recorded and further assessed into secondary screening. In the primary screen, highly effective compounds were tested again at lower MICs.

**Secondary screening for antifungal agent targeting PS synthesis and assessment of MICs.** Here, 96-well plates were set out with SD medium in one half (6 wells) and SD medium with 1 mM ethanolamine in the other half (6 wells). Reconstituted drug from the master plate was transferred to the first well to serially dilute the drug to half-concentration to obtain final concentrations of 5, 2.5, 1.25, 0.625, and 0.312  $\mu$ M and the control (without drug, DMSO vehicle only) to a final volume of 100  $\mu$ L. A total of 1,000 yeast cells were inoculated in each well and plates were incubated without agitation at 30°C. After



48 h of incubation, OD<sub>600</sub> measurements were performed using a Perkin Elmer EnVision2104 Multilabel Reader and visualized quantitatively by a heatmap using Prism version 8.0 (GraphPad Software, Inc.). Assays for bleomycin MICs were performed in sterile 96-well plates as described above, but starting from higher drug concentrations to determine the MIC in SD+Etn medium.

**PS synthase activity assay.** PS synthase assays were performed for *Sc* WT and *Sccho1Δ+CnCHO1* strains. Cells were grown at 30°C in SC-Ura medium to the exponential phase (OD<sub>600</sub> ≈ 0.6) and harvested at 1,500 × *g* for 10 min. The harvested cells were resuspended in breaking buffer (50 mM Tris-HCl [pH 7.5], 0.3 M sucrose, 10 mM 2-mercaptoethanol, and Roche EDTA-free protease inhibitor cocktail), mixed with glass beads (0.5-mm diameter), and lysed using a Mini-BeadBeater-16 (BioSpec Products, Bartlesville, OK). The cell lysate was centrifuged at 1,500 × *g* for 10 min at 4°C, and the supernatant was used as cell extracts. PS synthase activity was measured at 30°C for 20 min in 100 μL reaction mixture containing 50 mM Tris-HCl (pH 8.0), 0.6 mM MnCl<sub>2</sub>, 0.2 mM CDP-DAG, 4 mM Triton X-100, 0.5 mM (3-<sup>3</sup>H) serine (10,000 cpm/nmol), and 10 μg cell extracts (48). The effect of bleomycin was examined at a final concentration of 5 mM. A unit of PS synthase activity was defined as the amount of enzyme that catalyzed the formation of 1 nmol product/min per mg of protein (U = nmol/min/mg protein). The enzyme assays were performed in triplicate and repeated twice.

**Mitochondria and DNA staining, fluorescence microscopy, and flow cytometry.** Overnight yeast cells grown in 3 mL liquid SD medium at 30°C with constant agitation were collected at 3,000 × *g* for 2 min the next morning and transferred in SD and SD+Etn medium for 2 to 4 h. The initial cell density was adjusted to around OD<sub>600</sub> = 0.3 before treatment with bleomycin (2.5 μM for *Sc* and 5 μM for H99) for 10 h. Cells were harvested, washed once in PBS, and resuspended in PBS supplemented with 0.2 μM MitoTracker Deep Red FM (Invitrogen) and 1 μg of Hoechst 33342 (Thermo Fisher Scientific). Cells were incubated for 10 min at 30°C in the dark, washed twice with PBS, resuspended in PBS, and observed under a fluorescence microscope (Olympus BX61, Olympus Life Sciences). MitoTracker Deep Red fluorescence was detected by flow cytometry with a BD Via-Probe (BD Biosciences) using FL3 channel. The data were analyzed using FlowJo software (FlowJo LLC) and expressed as mean fluorescence intensity (MFI). All experiments were done in triplicate. Analysis was performed using the unpaired, two-tailed *t* test in GraphPad Prism version 8. *P* values of <0.05 were considered statistically significant.

**Measurement of ROS.** ROS production was detected using dichlorodihydrofluorescein diacetate by either flow cytometry or under a fluorescence microscope as previously reported (49, 50) but with slight modifications. Cells were grown overnight in 3 mL SD-Ura. The next day, cells were centrifuged at 3,000 × *g* for 2 min and incubated in fresh SD and SD+Etn medium for few hours until the cell density (OD<sub>600</sub>) reached around 0.3. Cells were treated with either 0.1% (vol/vol) DMSO (vehicle control) or bleomycin (2.5 μM for *Sc* and 5 μM for H99) and incubated at 30°C with constant agitation for 10 h. Cells were harvested from the culture medium and centrifuged at 3,000 × *g* for 2 min and washed with PBS. To detect ROS, cells were resuspended in PBS supplemented with H<sub>2</sub>DCFDA (Invitrogen) (2.5 μM for *Sc* and 5 μM for H99) and incubated in the dark at 30°C with constant agitation for 30 min. Cells were washed twice with PBS to remove excess dye and resuspended in PBS. Fluorescence signal was immediately detected by flow cytometry with BD Via based on FL1 channel to detect ROS. For microscopic analysis, cells were visualized at 100× magnification using a fluorescence microscope (Olympus BX61). Intracellular ROS levels were also measured with dihydroethidium (DHE, Invitrogen) as described previously in yeast cells, with some modifications (51). For the DHE assay, yeast cells were prepared in the same way. After treatment with bleomycin for 10 h, washed yeast cells were incubated with DHE (10 μM for *Sc* and 20 μM for H99) for 1 h. Cells were washed twice with water and 200-μL samples were added to each well of a 96-well microplate. A control set of samples incubated without fluorescent dye were included as unstained cells. ROS was measured as fluorescence emitted by the fluorescent dye using a SpectraMax iD5 Microplate Reader (Molecular Devices, San Jose, CA) with excitation and emission wavelengths of 518 and 606 nm, respectively. The obtained reading was normalized against the unstained cells and data were expressed as DHE fluorescence intensity. All experiments were done in triplicate. Analysis was performed using the unpaired, two-tailed *t* test in GraphPad Prism version 8. *P* values of <0.05 were considered statistically significant.

## ACKNOWLEDGMENTS

We thank the Medicines for Malaria Venture for supplying the Pathogen Box collection, the NIH Small Molecule Repository for supplying the NIH Clinical Collection compound library, and Rutgers University for supplying the FDA-approved compound library.

This work is supported by NIH grants R01AI123315 and R21AI154318 to C.X. and by NIH grant GM136128 to G.M.C.

## REFERENCES

- Bongomin F, Gago S, Oladele RO, Denning DW. 2017. Global and multi-national prevalence of fungal diseases: estimate precision. *J Fungi (Basel)* 3:57. <https://doi.org/10.3390/jof3040057>.
- Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, Denning DW, Loyal A, Boulware DR. 2017. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. *Lancet Infect Dis* 17:873–881. [https://doi.org/10.1016/S1473-3099\(17\)30243-8](https://doi.org/10.1016/S1473-3099(17)30243-8).
- Holeman CW, Jr., Einstein H. 1963. The toxic effects of amphotericin B in man. *Calif Med* 99:90–93.
- Ghannoum MA, Rice LB. 1999. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. *Clin Microbiol Rev* 12:501–517. <https://doi.org/10.1128/CMR.12.4.501>.
- Day JN, Chau TTH, Wolbers M, Mai PP, Dung NT, Mai NH, Phu NH, Nghia HD, Phong ND, Thai CQ, Thai LH, Chuong LV, Sinh DX, Duong VA, Hoang TN,



- Diep PT, Campbell JJ, Sieu TPM, Baker SG, Chau NVV, Hien TT, Lalloo DG, Farrar JJ. 2013. Combination antifungal therapy for cryptococcal meningitis. *N Engl J Med* 368:1291–1302. <https://doi.org/10.1056/NEJMoa1110404>.
6. Folk A, Cotoraci C, Balta C, Suciuc M, Herman H, Boldura OM, Dinescu S, Paiusan L, Ardelean A, Hermenean A. 2016. Evaluation of hepatotoxicity with treatment doses of flucytosine and amphotericin b for invasive fungal infections. *Biomed Res Int* 2016:5398730. <https://doi.org/10.1155/2016/5398730>.
  7. Verweij PE, Chowdhary A, Melchers WJ, Meis JF. 2016. Azole resistance in *Aspergillus fumigatus*: can we retain the clinical use of mold-active antifungal azoles? *Clin Infect Dis* 62:362–368. <https://doi.org/10.1093/cid/civ885>.
  8. Nywening AV, Rybak JM, Rogers PD, Fortwendel JR. 2020. Mechanisms of triazole resistance in *Aspergillus fumigatus*. *Environ Microbiol* 22:4934–4952. <https://doi.org/10.1111/1462-2920.15274>.
  9. Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA. 2013. Increasing echinocandin resistance in *Candida glabrata*: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. *Clin Infect Dis* 56:1724–1732. <https://doi.org/10.1093/cid/cit136>.
  10. Berman J, Krysan DJ. 2020. Drug resistance and tolerance in fungi. *Nat Rev Microbiol* 18:319–331. <https://doi.org/10.1038/s41579-019-0322-2>.
  11. Rella A, Farnoud AM, Del Poeta M. 2016. Plasma membrane lipids and their role in fungal virulence. *Prog Lipid Res* 61:63–72. <https://doi.org/10.1016/j.plipres.2015.11.003>.
  12. Cassilly CD, Reynolds TB. 2018. PS, it's complicated: the roles of phosphatidylserine and phosphatidylethanolamine in the pathogenesis of *Candida albicans* and other microbial pathogens. *J Fungi (Basel)* 4:28. <https://doi.org/10.3390/jof4010028>.
  13. Chen YL, Montedonico AE, Kauffman S, Dunlap JR, Menn FM, Reynolds TB. 2010. Phosphatidylserine synthase and phosphatidylserine decarboxylase are essential for cell wall integrity and virulence in *Candida albicans*. *Mol Microbiol* 75:1112–1132. <https://doi.org/10.1111/j.1365-2958.2009.07018.x>.
  14. Braun BR, van Het Hoog M, d'Enfert C, Martchenko M, Dungan J, Kuo A, Inglis DO, Uhl MA, Hogues H, Berriman M, Lorenz M, Levitin A, Oberholzer U, Bachewich C, Harcus D, Marciel A, Dignard D, Iouk T, Zito R, Frangeul L, Tekaiia F, Rutherford K, Wang E, Munro CA, Bates S, Gow NA, Hoyer LL, Kohler G, Morschhauser J, Newport G, Znaidi S, Raymond M, Turcotte B, Sherlock G, Costanzo M, Ihmels J, Berman J, Sanglard D, Agabian N, Mitchell AP, Johnson AD, Whiteway M, Nantel A. 2005. A human-curated annotation of the *Candida albicans* genome. *PLoS Genet* 1:36–57. <https://doi.org/10.1371/journal.pgen.0010001>.
  15. Pan J, Hu C, Yu JH. 2018. Lipid biosynthesis as an antifungal target. *J Fungi (Basel)* 4:50. <https://doi.org/10.3390/jof4020050>.
  16. Vance JE. 2015. Phospholipid synthesis and transport in mammalian cells. *Traffic* 16:1–18. <https://doi.org/10.1111/tra.12230>.
  17. Atkinson KD, Jensen B, Kolat AI, Storm EM, Henry SA, Fogel S. 1980. Yeast mutants auxotrophic for choline or ethanolamine. *J Bacteriol* 141:558–564. <https://doi.org/10.1128/jb.141.2.558-564.1980>.
  18. Carman GM, Kersting MC. 2004. Phospholipid synthesis in yeast: regulation by phosphorylation. *Biochem Cell Biol* 82:62–70. <https://doi.org/10.1139/o03-064>.
  19. Matsuo Y, Fisher E, Patton-Vogt J, Marcus S. 2007. Functional characterization of the fission yeast phosphatidylserine synthase gene, *pps1*, reveals novel cellular functions for phosphatidylserine. *Eukaryot Cell* 6:2092–2101. <https://doi.org/10.1128/EC.00300-07>.
  20. Konarzewska P, Wang Y, Han GS, Goh KJ, Gao YG, Carman GM, Xue C. 2019. Phosphatidylserine synthesis is essential for viability of the human fungal pathogen *Cryptococcus neoformans*. *J Biol Chem* 294:2329–2339. <https://doi.org/10.1074/jbc.RA118.006738>.
  21. Chen J, Stubbe J. 2005. Bleomycins: towards better therapeutics. *Nat Rev Cancer* 5:102–112. <https://doi.org/10.1038/nrc1547>.
  22. Chen J, Ghorai MK, Kenney G, Stubbe J. 2008. Mechanistic studies on bleomycin-mediated DNA damage: multiple binding modes can result in double-stranded DNA cleavage. *Nucleic Acids Res* 36:3781–3790. <https://doi.org/10.1093/nar/gkn302>.
  23. Allawzi A, Elajaili H, Redente EF, Nozik-Grayck E. 2019. Oxidative toxicology of bleomycin: role of the extracellular redox environment. *Curr Opin Toxicol* 13:68–73. <https://doi.org/10.1016/j.cotox.2018.08.001>.
  24. Andreyev AY, Kushnareva YE, Starkov AA. 2005. Mitochondrial metabolism of reactive oxygen species. *Biochemistry (Mosc)* 70:200–214. <https://doi.org/10.1007/s10541-005-0102-7>.
  25. Turrens JF. 2003. Mitochondrial formation of reactive oxygen species. *J Physiol* 552:335–344. <https://doi.org/10.1113/jphysiol.2003.049478>.
  26. Grant CM, MacIver FH, Dawes IW. 1997. Mitochondrial function is required for resistance to oxidative stress in the yeast *Saccharomyces cerevisiae*. *FEBS Lett* 410:219–222. [https://doi.org/10.1016/S0014-5793\(97\)00592-9](https://doi.org/10.1016/S0014-5793(97)00592-9).
  27. Wallach-Dayana SB, Izibicki G, Cohen PY, Gerstl-Golan R, Fine A, Breuer R. 2006. Bleomycin initiates apoptosis of lung epithelial cells by ROS but not by Fas/FasL pathway. *Am J Physiol Lung Cell Mol Physiol* 290:L790–L796. <https://doi.org/10.1152/ajplung.00300.2004>.
  28. Chen X, Zhong Z, Xu Z, Chen L, Wang Y. 2010. 2',7'-Dichlorodihydrofluorescein as a fluorescent probe for reactive oxygen species measurement: forty years of application and controversy. *Free Radic Res* 44:587–604. <https://doi.org/10.3109/10715761003709802>.
  29. Cassilly CD, Maddox MM, Cherian PT, Bowling JJ, Hamann MT, Lee RE, Reynolds TB. 2016. SB-224289 antagonizes the antifungal mechanism of the marine depsipeptide papuamide A. *PLoS One* 11:e0154932. <https://doi.org/10.1371/journal.pone.0154932>.
  30. Burger RM, Peisach J, Horwitz SB. 1981. Activated bleomycin. A transient complex of drug, iron, and oxygen that degrades DNA. *J Biol Chem* 256:11636–11644. [https://doi.org/10.1016/S0021-9258\(19\)68452-8](https://doi.org/10.1016/S0021-9258(19)68452-8).
  31. Jayaguru P, Raghunathan M. 2007. Group I intron renders differential susceptibility of *Candida albicans* to bleomycin. *Mol Biol Rep* 34:11–17. <https://doi.org/10.1007/s11033-006-9002-1>.
  32. Hecht SM. 1994. RNA degradation by bleomycin, a naturally occurring bioconjugate. *Bioconjug Chem* 5:513–526. <https://doi.org/10.1021/bc00030a006>.
  33. Ekimoto H, Takahashi K, Matsuda A, Takita T, Umezawa H. 1985. Lipid peroxidation by bleomycin-iron complexes *in vitro*. *J Antibiot (Tokyo)* 38:1077–1082. <https://doi.org/10.7164/antibiotics.38.1077>.
  34. Graybill JR, Bocanegra R, Fothergill A, Rinaldi MG. 1996. Bleomycin therapy of experimental disseminated candidiasis in mice. *Antimicrob Agents Chemother* 40:816–818. <https://doi.org/10.1128/AAC.40.3.816>.
  35. Moore CW, McKoy J, Del Valle R, Armstrong D, Bernard EM, Katz N, Gordon RE. 2003. Fungal cell wall septation and cytokinesis are inhibited by bleomycins. *Antimicrob Agents Chemother* 47:3281–3289. <https://doi.org/10.1128/AAC.47.10.3281-3289.2003>.
  36. Costantini P, Jacotot E, Decaudin D, Kroemer G. 2000. Mitochondrion as a novel target of anticancer chemotherapy. *J Natl Cancer Inst* 92:1042–1053. <https://doi.org/10.1093/jnci/92.13.1042>.
  37. Joshi AS, Thompson MN, Fei N, Huttemann M, Greenberg ML. 2012. Cardiolipin and mitochondrial phosphatidylethanolamine have overlapping functions in mitochondrial fusion in *Saccharomyces cerevisiae*. *J Biol Chem* 287:17589–17597. <https://doi.org/10.1074/jbc.M111.330167>.
  38. Gohil VM, Thompson MN, Greenberg ML. 2005. Synthetic lethal interaction of the mitochondrial phosphatidylethanolamine and cardiolipin biosynthetic pathways in *Saccharomyces cerevisiae*. *J Biol Chem* 280:35410–35416. <https://doi.org/10.1074/jbc.M505478200>.
  39. Carman GM, Henry SA. 1999. Phospholipid biosynthesis in the yeast *Saccharomyces cerevisiae* and interrelationship with other metabolic processes. *Prog Lipid Res* 38:361–399. [https://doi.org/10.1016/S0163-7827\(99\)00010-7](https://doi.org/10.1016/S0163-7827(99)00010-7).
  40. Carman GM, Han GS. 2011. Regulation of phospholipid synthesis in the yeast *Saccharomyces cerevisiae*. *Annu Rev Biochem* 80:859–883. <https://doi.org/10.1146/annurev-biochem-060409-092229>.
  41. Mayer FL, Kronstad JW. 2017. Discovery of a novel antifungal agent in the Pathogen Box. *mSphere* 2:e00120-17. <https://doi.org/10.1128/mSphere.00120-17>.
  42. Vila T, Lopez-Ribot JL. 2017. Screening the Pathogen Box for identification of *Candida albicans* biofilm inhibitors. *Antimicrob Agents Chemother* 61:e02006-16. <https://doi.org/10.1128/AAC.02006-16>.
  43. Vezina C, Kudelski A, Sehgal SN. 1975. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. *J Antibiot (Tokyo)* 28:721–726. <https://doi.org/10.7164/antibiotics.28.721>.
  44. Wong GK, Griffith S, Kojima I, Demain AL. 1998. Antifungal activities of rapamycin and its derivatives, prolylrapamycin, 32-desmethylrapamycin, and 32-desmethoxyrapamycin. *J Antibiot (Tokyo)* 51:487–491. <https://doi.org/10.7164/antibiotics.51.487>.
  45. Reeder NL, Xu J, Youngquist RS, Schwartz JR, Rust RC, Saunders CW. 2011. The antifungal mechanism of action of zinc pyrithione. *Br J Dermatol* 165 Suppl 2:9–12. <https://doi.org/10.1111/j.1365-2133.2011.10571.x>.
  46. Xu Y, Pang G, Zhao D, Gao C, Zhou L, Sun S, Wang B. 2010. *In vitro* activity of thimerosal against ocular pathogenic fungi. *Antimicrob Agents Chemother* 54:536–539. <https://doi.org/10.1128/AAC.00714-09>.
  47. Xu Y, Zhao D, Gao C, Zhou L, Pang G, Sun S. 2012. *In vitro* activity of phenylmercuric acetate against ocular pathogenic fungi. *J Antimicrob Chemother* 67:1941–1944. <https://doi.org/10.1093/jac/dks133>.

48. Bae-Lee MS, Carman GM. 1984. Phosphatidylserine synthesis in *Saccharomyces cerevisiae*. Purification and characterization of membrane-associated phosphatidylserine synthase. *J Biol Chem* 259:10857–10862. [https://doi.org/10.1016/S0021-9258\(18\)90592-2](https://doi.org/10.1016/S0021-9258(18)90592-2).
49. Peng CA, Gaertner AAE, Henriquez SA, Fang D, Colon-Reyes RJ, Brumaghim JL, Kozubowski L. 2018. Fluconazole induces ROS in *Cryptococcus neoformans* and contributes to DNA damage *in vitro*. *PLoS One* 13: e0208471. <https://doi.org/10.1371/journal.pone.0208471>.
50. Dbouk NH, Covington MB, Nguyen K, Chandrasekaran S. 2019. Increase of reactive oxygen species contributes to growth inhibition by fluconazole in *Cryptococcus neoformans*. *BMC Microbiol* 19:243. <https://doi.org/10.1186/s12866-019-1606-4>.
51. Perez-Gallardo RV, Briones LS, Diaz-Perez AL, Gutierrez S, Rodriguez-Zavala JS, Campos-Garcia J. 2013. Reactive oxygen species production induced by ethanol in *Saccharomyces cerevisiae* increases because of a dysfunctional mitochondrial iron-sulfur cluster assembly system. *FEMS Yeast Res* 13:804–819. <https://doi.org/10.1111/1567-1364.12090>.
52. Perfect JR, Schell WA, Rinaldi MG. 1993. Uncommon invasive fungal pathogens in the acquired immunodeficiency syndrome. *J Med Vet Mycol* 31:175–179. <https://doi.org/10.1080/02681219380000211>.